On March 4, 2021 Aileron Therapeutics (NASDAQ:ALRN) reported that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation at the 2021 H.C. Wainwright Global Life Sciences Conference, which is taking place March 9 – 10, 2021 (Press release, Aileron Therapeutics, MAR 4, 2021, View Source [SID1234576049]). Dr. Aivado’s presentation will include an overview of Aileron’s upcoming Phase 1b placebo-controlled trial of ALRN-6924 in patients with advanced p53-mutated non-small cell lung cancer, anticipated to begin in the second quarter of 2021, including the company’s target enrollment expansion announced earlier this week.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation will be available on demand under the Investors and Media section of Aileron’s website at View Source beginning March 9, 2021 at 7:00 a.m. EST. A replay of the webcast will be archived on Aileron’s website for 90 days following the event.